PRIMARY STUDY

Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.

Key Findings:  Findings point to a possible effect of CBD in improving quality of life measures in PD patients with no psychiatric comorbidities; however, studies with larger samples and specific objectives are required before definitive conclusions can be drawn.

Type of Study:  Human Trial

Study Sample Size:  21

Study Result:  Positive


Cannabinoids Studied:  Cannabidiol (CBD)

Phytocannabinoid Source:  Unspecified

Chemotype:  Chemotype III

Form of Administration:  Not Applicable

Sub-Ratio: 0:1 (THC:CBD)

Dosage: Three study groups: CBD (75 mg/day), CBD (300 mg/day), or placebo


Study Location(s):  Brazil

Year of Pub:  2014


Link to study